Craig Coleman, PharmD, FASHP, FACC, Professor at the University of Connecticut discusses new data supporting XARELTO ® (rivaroxaban) efficacy and safety compared to warfarin in patients with nonvalvular atrial fibrillation (NVAF) and concomitant obstructive sleep apnea (OSA) which was published in “TH Open”, a peer-reviewed vascular biology and medicine journal.
Craig I. Coleman earned his bachelor’s degree from Clark University in Worcester, MA, and his Doctor of Pharmacy degree from the University of Connecticut School of Pharmacy, Storrs, USA. He then completed a two-year research fellowship at Hartford Hospital, CT, where he specialized in health outcomes and economics research. As of 2003, Professor Coleman has been employed in a full-time faculty position at the University of Connecticut. He was granted tenure in 2009 and promoted to full professor in 2013. Until recently, he served as Co-Director and Methods-Chief for UConn’s Agency for Healthcare and Research Quality (AHRQ) Evidence-Based Practice Center.
Professor Coleman has co-authored more than 340 publications in peer-reviewed journals, including JAMA, Annals of Internal Medicine, The Lancet, Circulation, European Heart Journal, Chest, Diabetes Care, Journal of Thrombosis and Haemostasis, Thrombosis and Haemostasis and Critical Care.